VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Celldex Therapeutics Executive Compensation (FY25)

CLDX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Anthony Marucci
Latest say-on-pay support
=
June 25, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Celldex Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 6, 2026Latest filing (8-K): June 26, 2026
15 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Celldex Therapeutics brief$500Get the executive brief
Velarion Intel, one year, every company
261 figures on this page: 250 cited to the filing that reported them, 11 calculated from figures it prints. See the citations

More on Celldex Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Anthony Marucci: $9,229,165 → $5,366,709 (41.9% lower)
Say-on-pay support: 98.8% → 98.4% (0.4 points lower)
CEO pay ratio: 39:1 → 23:1 (41.0% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Celldex Therapeutics' chief executive and what were they paid?
Total compensation for Anthony Marucci, President, Chief Executive Officer and Director, came to $5,366,709 in fiscal 2025. Marucci's total moved 41.9% lower from the $9,229,165 reported for fiscal 2024.
What was Celldex Therapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 98.4% of votes cast for or against in favor at the meeting held June 25, 2026 for fiscal 2025.
Which companies are in Celldex Therapeutics' peer group?
The disclosed peer group names Apellis Pharmaceuticals, Arcellx, Arvinas, Biohaven and BridgeBio Pharma, among others.
What is Celldex Therapeutics' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 23:1, against median employee compensation of $235,733.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Anthony Marucci
President, Chief Executive Officer and Director
◇◇—◇——◇◇
Tibor Keler
Executive Vice President and Chief Scientific Officer
◇◇—◇——◇◇
Sam Martin
Senior Vice President, Chief Financial Officer and Secretary
◇◇—◇——◇◇
Diane Young
Senior Vice President, Chief Medical Officer
◇◇—◇——◇◇
Margo Heath-Chiozzi
Senior Vice President, Regulatory Affairs
◇◇—◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Anthony Marucci
President, Chief Executive Officer and Director
◇◇—◇——◇◇
Tibor Keler
Executive Vice President and Chief Scientific Officer
◇◇—◇——◇◇
Diane Young
Senior Vice President, Chief Medical Officer
◇◇—◇——◇◇
Sam Martin
Senior Vice President, Chief Financial Officer and Secretary
◇◇—◇——◇◇
Margo Heath-Chiozzi
Senior Vice President, Regulatory Affairs
◇◇—◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Anthony Marucci
President and Chief Executive Officer
◇◇—◇——◇◇
Tibor Keler
Executive Vice President and Chief Scientific Officer
◇◇—◇——◇◇
Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
◇◇—◇——◇◇
Margo Heath-Chiozzi
Senior Vice President, Regulatory Affairs
◇◇—◇——◇◇
Sam Martin
Senior Vice President and Chief Financial Officer
◇◇—◇——◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Anthony Marucci
President, Chief Executive Officer and Director
◇◇—◇——◇◇
Tibor Keler
Executive Vice President and Chief Scientific Officer
◇◇—◇——◇◇
Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
◇◇—◇——◇◇
Sam Martin
Senior Vice President, Chief Financial Officer and Secretary
◇◇—◇——◇◇
Margo Heath-Chiozzi
Senior Vice President, Regulatory Affairs
◇◇—◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Anthony S. MarucciOPTION◇——◇—◇◇
Elizabeth CrowleyOPTION◇——◇—◇◇
Margo Heath-ChiozziOPTION◇——◇—◇◇
Sam MartinOPTION◇——◇—◇◇
Tibor KelerOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Anthony MarucciOption◇—◇6/5/35
Option◇—◇6/13/34
Option◇—◇6/15/33
Option◇—◇6/16/32
Tibor KelerOption◇—◇6/5/35
Option◇—◇6/13/34
Option◇—◇6/15/33
Option◇—◇6/16/32
Elizabeth CrowleyOption◇—◇6/5/35
Option◇—◇6/13/34
Option◇—◇6/15/33
Option◇—◇6/16/32
Margo Heath-ChiozziOption◇—◇6/5/35
Option◇—◇6/13/34
Option◇—◇6/15/33
Option◇—◇6/16/32
Sam MartinOption◇—◇6/5/35
Option◇—◇6/13/34
Option◇—◇6/15/33
Option◇—◇6/16/32
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Elizabeth Crowley
Senior Vice President, Chief Product Development Officer · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Margo Heath-Chiozzi
Senior Vice President, Regulatory Affairs · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Sam Martin
Senior Vice President, Chief Financial Officer and Secretary · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Tibor Keler
Executive Vice President and Chief Scientific Officer · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Denice Torres
◇—◇———◇
Harry H. Penner, Jr
Board chair
◇—◇———◇
James J. Marino
◇—◇———◇
Keith L. Brownlie
◇—◇———◇
Garry A. Neil, M.D
◇—◇———◇
Cheryl L. Cohen
◇—◇———◇
Herbert J. Conrad
◇—◇———◇
Rita I. Jain, M.D
◇—◇———◇
Anthony S. Marucci served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Stock Options.
Stock ownership guideline: 3x annual retainer ($144,000)

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Apellis Pharmaceuticals APLS
  • Arcellx ACLX
  • Arvinas ARVN
  • Biohaven BHVN
  • BridgeBio Pharma BBIO
  • CRISPR Therapeutics CRSP
  • Cytokinetics CYTK
  • Denali Therapeutics DNLI
  • ImmunityBio IBRX
  • Immunovant IMVT
  • Inhibrx INBX
  • Keros Therapeutics KROS
  • Kiniksa Pharmaceuticals KNSA
  • Madrigal Pharmaceuticals MDGL
  • Protagonist Therapeutics PTGX
  • Roivant Sciences ROIV
  • SpringWorks Therapeutics SWTX
  • Syndax Pharmaceuticals SNDX
  • Vaxcyte PCVX
  • Zentalis Pharmaceuticals ZNTL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 25, 2026=◇◇◇
2024June 5, 2025=◇◇◇
2023June 13, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2021June 16, 2022=◇◇◇
2020June 17, 2021=◇◇◇
2019June 18, 2020=◇◇◇
2018June 19, 2019=◇◇◇
2017June 13, 2018=◇◇◇
2016June 15, 2017=◇◇◇
2015June 8, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Anthony Marucci (President, Chief Executive Officer and Director), FY2025 total compensation $5,366,709 (base salary $785,804) [exec_comp, SEC accession 0001104659-26-050884, filed 2026-04-29]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Celldex Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Celldex Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Celldex Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Celldex Therapeutics' disclosed peer group is defensible, who names Celldex Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
261 figures on this page: 250 cited to the filing that reported them, 11 calculated from figures it prints.
250 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001104659-26-078023
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001104659-26-050884
    CEO Pay Ratio · DIRECTORS & · Director Compensation · Outstanding Equity Awards at Fiscal Year-End · and 1 more section
  3. 0001104659-26-019652
    EX-10.10 · EX-10.14 · EX-10.15 · Exhibit
  4. 0001104659-25-057066
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001104659-25-036562
    Summary Compensation Table
  6. 0001104659-24-071512
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001104659-24-051634
  8. 0001104659-23-071597
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001104659-22-071880
  10. 0001104659-21-082585
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001104659-20-074646
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001104659-19-036671
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001104659-18-040165
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001104659-17-039747
    Item 5.07 Submission of Matters to a Vote of Security Holders
  15. 0001104659-16-126316
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Celldex Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CLDX (accessed 2026).
Short form: data: Velarion

The paid brief for Celldex Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
15 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Celldex Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Celldex Therapeutics discloses

The companies named in CLDX's own disclosed peer group.

Apellis PharmaceuticalsArcellxArvinasBiohavenBridgeBio PharmaCRISPR TherapeuticsCytokineticsDenali TherapeuticsImmunityBioImmunovantInhibrxKeros TherapeuticsKiniksa PharmaceuticalsMadrigal PharmaceuticalsProtagonist TherapeuticsRoivant SciencesSpringWorks TherapeuticsSyndax PharmaceuticalsVaxcyteZentalis Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy